Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Mihai Cosmin Stan"'
Autor:
Mihai Cosmin Stan, Doru Paul
Publikováno v:
Oncology Reviews, Vol 18 (2024)
This paper presents an overview of the interconnection between various factors related to both cancer and type 2 diabetes mellitus (T2DM). Hyperglycemia, hyperinsulinemia, chronic inflammation, and obesity are involved in the development and progress
Externí odkaz:
https://doaj.org/article/cbcdf62113f54272bcff641dea6d7c93
Autor:
Camil Ciprian MIRESTEAN, Mihai Cosmin STAN, Roxana Irina IANCU, Dragos Petru Teodor IANCU, Florinel BADULESCU
Publikováno v:
Modern Medicine, Vol 30, Iss 3, Pp 175-180 (2023)
The majority of skin cancers of the head and neck are represented by basal cell carcinoma (BCC) and cutaneous squamosal cell carcinoma (CSCC), both non-melanoma skin cancers. Identified in the early stages, the cure rate is considered high. Sun prote
Externí odkaz:
https://doaj.org/article/19b0340e8fa04b4e88e93c508a0ebe57
Autor:
Camil Ciprian MIRESTEAN, Roxana Irina IANCU, Mihai Cosmin STAN, Dragos Petru Teodor IANCU, Florinel BADULESCU
Publikováno v:
Modern Medicine, Vol 30, Iss 1, Pp 23-28 (2023)
Concurrent chemo-radiotherapy with Cisplatin is the standard treatment for locally advanced non-metastatic squamous cell carcinoma of the head and neck (HNSCC), but induction chemotherapy (IC) followed by chemo-irradiation, even controversial is a wi
Externí odkaz:
https://doaj.org/article/316be8a963e24d61bf17636ca9b32f40
Autor:
Camil Ciprian Mireștean, Mihai Cosmin Stan, Roxana Irina Iancu, Dragoș Petru Teodor Iancu, Florinel Bădulescu
Publikováno v:
Diagnostics, Vol 13, Iss 22, p 3396 (2023)
Introduction: Neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and pallets-to-lymphocyte ratio (PLR) are currently validated as cheap and accessible biomarkers in different types of solid tumors, including head and neck cance
Externí odkaz:
https://doaj.org/article/664509429c2f4ead89a5eb5d8c3ae3af
Autor:
Camil Ciprian Mireștean, Cristiana Eugenia Simionescu, Roxana Irina Iancu, Mihai Cosmin Stan, Dragoș Petru Teodor Iancu, Florinel Bădulescu
Publikováno v:
Diagnostics, Vol 13, Iss 19, p 3026 (2023)
Chondrosarcoma represents approximately 0.1% of all neoplasms of the head and neck and is considered a rare disease with a relatively good prognosis. The 5-year overall survival (OS) rate is estimated at 70–80%, being considered a disease with a lo
Externí odkaz:
https://doaj.org/article/ec90a62134414a2fa47084ed7604e613
Autor:
Camil Ciprian Mireștean, Mihai Cosmin Stan, Michael Schenker, Constantin Volovăț, Simona Ruxandra Volovăț, Dragoș Teodor Petru Iancu, Roxana Irina Iancu, Florinel Bădulescu
Publikováno v:
Diagnostics, Vol 13, Iss 16, p 2620 (2023)
Prognosis in recurrent/metastatic head and neck squamous-cell carcinoma (HNSCC) refractory to platinum-based chemotherapy is poor, making therapy optimization a priority. Anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody Nivolumab
Externí odkaz:
https://doaj.org/article/e9598733e8e942289a0359c6ac798936
Publikováno v:
Diagnostics, Vol 13, Iss 16, p 2647 (2023)
Background and Objectives: A growing number of epidemiological studies have suggested that diabetes mellitus may increase cancer risk and is implicated in numerous other metabolic and inflammatory disorders. The increase in proinflammatory cytokines
Externí odkaz:
https://doaj.org/article/f3588f5e430641488603e154cb1aaa70
Publikováno v:
Bratislava Medical Journal.
Autor:
Camil Ciprian Mireștean, Mihai Cosmin Stan, Michael Schenker, Constantin Volovăț, Simona Ruxandra Volovăț, Dragoș Petru Teodor Iancu, Roxana Irina Iancu, Badulescu Florinel
The prognosis of patients with recurrent or metastatic of the head and neck squamous-cell carcinoma (HNSCC) refractory to platinum-based chemotherapy is severe and, consequently, the identification of therapeutic options for this category of patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b46678dab5c21d4bbdf64addbe5a7515
https://doi.org/10.20944/preprints202305.0561.v1
https://doi.org/10.20944/preprints202305.0561.v1
Publikováno v:
Oncolog-Hematolog.ro. 3